Combination of LCZ696 and ACEI further improves heart failure and myocardial fibrosis after acute myocardial infarction in mice

Liu, Youbin; Fan, Yuxin; Li, Jinglong; Meng, Chen; Chen, Anyong; Yang, Dawei; Guan, Xue; Cao, Yunshan

doi:10.1016/j.biopha.2020.110824

“…The remaining 97 articles were integrated, similar 67 articles were removed, 30 articles were classified, and 30 articles were intensively read in full text. There were 23 articles and 2024 cases [ 11 ].…”

Section: Resultsmentioning

confidence: 99%

Meta-Analysis of the Effects of Recombinant Human Brain Natriuretic Peptides on Left Ventricular Remodeling in Patients with Acute Myocardial Infarction

Zhu

¹

2022

Computational and Mathematical Methods in Medicine

View full text Add to dashboard Cite

Objective. Systematic evaluation of the efficacy of natriuretic recombination in human brain on disease myocardial infarction, left ventricular heart failure, and the efficacy and safety of long-term left ventricular remodeling. Methods. Computerized search of CNKI, Wanfang database, Wipro Chinese Technology Publications (VIP) numerical database, Chinese Biomedical Literature Database (CBM), Medline Cochrane Library, clinical Trail.Gov clinical collection, and other documents. Randomized controlled trials (RCT) of recombinant human brain natriuretic peptide in the treatment of acute myocardial infarction from inception to December 2021 were searched. Based on the Jadad scale, inclusion-exclusion data for diseases were collected and elaborated by meta by RevMan 5.3 simulation software. In a total of 23 randomized controlled trials, 2 024 cases were used as the basic data, the control group was routinely treated for 1 012 cases, and 1 012 cases in the experimental group were also treated with natriuretic peptide in the recombinant human brain on the previous basis. Results. In terms of overall efficacy, the experimental group was better than the control group, statistically significant ( OR = 4.30 , 95% CI (3.26, 5.67), P < 0.000 01 ), left ventricular ejection fraction in the experimental group than the control group ( OR = 1.58 , 95% CI (1.27, 1.90), P < 0.000 01 ). In terms of a myocardial strain in the left ventricle, the experimental group was superior to the control group. The difference was significant ( OR = − 0.91 , 95% CI (-1.50, -0.33), P = 0.002 ). In terms of the cardiac output volume, the experimental group was superior to the control group ( OR = 1.24 , 95% CI (0.55, 1.94), P = 0.0005 ). Regarding brain natriuretic peptide precursors, the experimental group was superior to the control group ( OR = − 4.37 , 95% CI (-6.21, -3.25), P < 0.00001 ). In terms of the heart rate, the experimental group was superior to the control group. Measurement of differential significance is as follows: OR = − 13.70 , 95% CI (-14.95, -12.46), P < 0.00001 . In terms of contraction, the experimental group was superior to the comparison group ( OR = − 12.38 , 95% CI (-17.98, -6.79), P < 0.00001 ). The experimental group outperformed the control group ( OR = − 7.42 , 95% CI (-8.53, -6.30), P < 0.00001 ). In terms of bad influence, the measurement is as follows: OR = 0.95 , 95% CI (0.29, 3.16), P = 0.94 . Conclusion. In patients with acute myocardial infarction and left ventricular remodeling, if treated with a heavy treatment of the group of cerebral natriuretic peptide mode, it can increase clinical treatment, improve the cardiac effect, inhibit ventricular remodeling, improve blood pressure and heart rhythm, and have greater clinical treatment and safety.

show abstract

“…SGLT2 inhibitor is a new type of hypoglycemic agent, and various SGLT2 inhibitors can significantly reduce the left ventricle ejection fraction of patients in several large-scale recently finished and underway clinical studies, which is expected to reduce the mortality of heart failure patients. More importantly, these benefits can be observed in patients with or without diabetes mellitus, suggesting that the benefits are independent of the effects on reducing blood glucose [ 13 , 14 ]. The tablet of oral dapagliflozin (a SGLT2 inhibitor) has been approved by the Food and Drug Administration (FDA) used for the treatment of heart failure on May 5, 2020 (CAS registration no.…”

Section: Discussionmentioning

confidence: 99%

Effect of Dapagliflozin on Indicators of Myocardial Fibrosis and Levels of Inflammatory Factors in Heart Failure Patients

Wang

¹

,

Qin

²

,

Zhang

³

et al. 2022

View full text Add to dashboard Cite

Objective. To explore the effect of dapagliflozin on the myocardial fibrosis and the levels of inflammatory factors in heart failure patients. Methods. 60 patients with T2DM who were diagnosed as acute left heart failure or acute exacerbation of chronic left heart failure in the Department of Cardiology of our hospital from November 1, 2020, to December 31, 2021, during hospitalization were the study subjects. According to the treatment regimen, they were divided into the experimental group (EG) which received dapagliflozin and conventional drugs and the control group (CG) which received conventional drugs, with 30 cases in each group to compare and analyze the clinical indicators such as myocardial fibrosis and inflammatory factors. Results. The levels of TNF-α, IL-1β, IL-6, and hs-CRP in the two groups were decreased gradually after treatment, and the levels of TNF-α, IL-1β, IL-6, and hs-CRP in the EG were visibly lower compared with those in the CG at week 4 of treatment ( P < 0.05 ). The cardiac function evaluation of patients showed that the levels of LVEF and LVEDD in both groups were gradually improved after treatment, with a significant difference from the fourth week. In other words, compared with the CG, the LVEF level in the EG was obviously higher ( P < 0.05 ), the LVEDD level was distinctly lower ( P < 0.05 ), and the levels of ST2, BNP, and MCP-1 in the EG were clearly lower at week 4 of treatment ( P < 0.05 ) with a statistical significance in difference. Conclusion. Dapagliflozin has a definite curative effect in heart failure patients with type 2 diabetes mellitus, which can effectively reduce the inflammatory response of patients and inhibit the myocardial fibrosis, and has a potential value in improving cardiac function and promoting prognosis.

show abstract

“…Acute myocardial infarction (AMI) is characterized by sudden onset, rapid advancement and high mortality. Therefore, patients should be sent to hospital for emergency treatment as soon as they show signs of AMI [17][18][19]. One of the most frequently used methods for the treatment of myocardial infarction is PCI.…”

Section: Discussionmentioning

confidence: 99%

Combined administration of nicorandil and atorvastatin in patients with acute myocardial infarction after coronary intervention, and its effect on postoperative cardiac systolic function

Sun¹,

Zhang²,

Shen³

2021

Trop. J. Pharm Res

0

View full text Add to dashboard Cite

Purpose: To study the effect of a combination of nicorandil and atorvastatin calcium in patients with acute myocardial infarction after coronary intervention, and its effect on postoperative cardiac systolic function of patients.Methods: Retrospective analysis was performed on 100 patients with acute myocardial infarctiontreated with coronary interventional therapy in The Third Affiliated Hospital of Qiqihaer MedicalUniversity from April 2019 to August 2020. The patients were randomised into control and study groups, with 50 patients in each group. The control group was treated with nicorandil, while the study group was treated with a combination of nicorandil and atorvastatin. Treatment response, cardiac structural indices, cardiac systolic function, blood lipid profiles, quality of life (QLI) score, Barthel Index (BI), Fugl- Meyer assessment (FMA), motor function score, incidence of adverse reactions, and blood pressure changes on days 1, 2, 3 and 4 after surgery, were compared between the two groups.Results: Treatment effectiveness, cardiac systolic function, QLI score, BI index and FMA motor function score in the study group were higher than the corresponding control values (p < 0.05). However, lower cardiac structure indices, blood lipid profiles and incidence of adverse reactions were greater in the study group than in the control group (p < 0.05). No significant disparity in blood pressure was found between the two groups on post-surgery days 1, 2, 3 and 4.Conclusion: The combination of nicorandil and atorvastatin calcium tablets produced better outcomes in patients with acute myocardial infarction after coronary intervention therapy; furthermore, the combination therapy significantly improved the cardiac systolic function of patients.

show abstract

Combination of LCZ696 and ACEI further improves heart failure and myocardial fibrosis after acute myocardial infarction in mice

Cited by 17 publications

References 27 publications

Meta-Analysis of the Effects of Recombinant Human Brain Natriuretic Peptides on Left Ventricular Remodeling in Patients with Acute Myocardial Infarction

Meta-Analysis of the Effects of Recombinant Human Brain Natriuretic Peptides on Left Ventricular Remodeling in Patients with Acute Myocardial Infarction

Effect of Dapagliflozin on Indicators of Myocardial Fibrosis and Levels of Inflammatory Factors in Heart Failure Patients

Combined administration of nicorandil and atorvastatin in patients with acute myocardial infarction after coronary intervention, and its effect on postoperative cardiac systolic function

Contact Info

Product

Resources

About